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We report on an Ebola virus disease (EVD) survivor who
showed Ebola virus in seminal ﬂuid 531 days after onset of dis-
ease. The persisting virus was sexually transmitted in February
2016, about 470 days after onset of symptoms, and caused a new
cluster of EVD in Guinea and Liberia.
Keywords. Ebola virus; sexual transmission; seminal ﬂuid;
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On 29 December 2015, theWorld Health Organization declared
the end of Ebola virus (EBOV) transmission in the Republic of
Guinea. On 16 March 2016, the health authorities of
N’Zérékoré, Guinea, classiﬁed 3 community deaths that had oc-
curred between 27 February and 15 March 2016 in the Koro-
para subprefecture as probable Ebola virus disease (EVD)
cases (Figure 1A, cases 1–3) [1]. A national investigation team
was deployed on 17 March in the region. Subsequently, several
contacts of probable cases 1, 2, and 3—mostly family members
in Koropara and Macenta prefecture—were diagnosed with
EVD by EBOV real-time reverse-transcription polymerase
chain reaction (RT-PCR) (Figure 1A, cases 4–10). In addition,
the disease further spread to Liberia.
As of 29 April 2016, Guinea had recorded 3 probable and 7
conﬁrmed cases, of which 6 were admitted at an Ebola treatment
unit (ETU). Four patients died in the community and 4 patients
in the ETU. Thus, the overall fatality ratio among probable and
conﬁrmed cases in this cluster in Guinea was 80% (8/10).
The National Committee of Ethics in Medical Research of Guin-
ea approved the use of diagnostic leftover samples and correspond-
ing patient data for this study (permits Nº11/CNERS/14). All
necessary consent required by applicable law from the patients
whose information is included in the article was obtained in writing.
The long gap between the new cluster and previous cases in
Guinea and the location of N’Zérékoré in the forest region of
Guinea near the presumed source of the epidemic raised the
possibility of a new spillover event from an animal reservoir. Al-
ternative hypotheses included transmission from an EVD sur-
vivor or an undetected unbroken chain of human-to-human
transmission. Virus genome sequencing can determine which
of these scenarios are most likely. Therefore, blood samples
from cases 4 and 5 were collected on 18 March and sent to
the sequencing facility of the European Mobile Laboratory in
Nongo, Conakry. Real-time sequencing was performed using
MinION technology (Oxford Nanopore) as described by
Quick et al [2], with results available on 20 March 2016. Valida-
tion sequencing was performed by the University of Makeni lab-
oratory, Sierra Leone, on the Ion Torrent platform. A database of
1066 previously sequenced EBOV genomes was used to place the
sequences into geographical and historical context. Viruses from
cases 4 and 5 were genetically indistinguishable by both methods
of sequencing. They were closely related to viruses from the
2014–2016 outbreak, ruling out a new introduction from an an-
imal reservoir. Notably, the viruses did not belong to the GN1 or
SL3 lineages that were circulating in Guinea in the second half of
2015 [2], but instead to a cluster of cases from N’Zérékoré and
Macenta that was last detected in 2014 (Figure 1B; Supplementa-
ry Figure 1) [3, 4]. The most closely related sequence in the data-
base (EM_076610; accession number KR817153) had been
obtained from a male patient on admission to the ETU in Guéck-
édou in November 2014 (he survived) (Figure 1B) [3].
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Independently and in parallel, epidemiological investigation
identiﬁed the same survivor as the likely source of the new
EVD cluster. On 19 March, the investigation revealed that
case 1 had sexual intercourse with a male EVD survivor from
the village of Koropara Centre (Figure 1A, “survivor”). He
had been treated in the ETU of Guéckédou from 3 to 14 No-
vember 2014. On admission, the cycle threshold (Ct) value in
the RealStar Filovirus Screen RT-PCR (Altona Diagnostics)
was 22 (the sequence of that sample [EM_076610; accession
number KR817153] was available in the database). He reported
sexual abstinence from discharge in November 2014 through
August 2015 as recommended by current protocols. From Sep-
tember 2015, he had occasional sexual intercourse with various
partners, including case 1 at the end of January 2016. Except
for episodes of asthenia, he reported no post-EVD complications.
In March 2016, a rapid diagnostic test for human
immunodeﬁciency virus types 1 and 2 (Alere Determine HIV-
1/2) was negative. A seminal ﬂuid sample obtained on 21
March was positive for EBOV with a Ct value of 23.4 in the Real-
Star Zaire Ebolavirus RT-PCR (Altona Diagnostics). On 9 April
2016, seminal ﬂuid still tested positive with a Ct value of 32.4.
EBOV in seminal ﬂuid from 21 March was sequenced in
Guinea and in Sierra Leone as described above. On 23 March,
the results revealed that the virus was identical to that of acute
cases 4 and 5 (Figure 1B), supporting the epidemiological evi-
dence of sexual transmission. Additional sequencing and phy-
logenetic analysis of 7 acute cases conﬁrmed that the entire
cluster is linked with the survivor. The sequences are either
identical to or only differ by up to 1 nucleotide from that of
the survivor’s semen (Figure 1B; Supplementary Table 1).
The PCR and sequencing data strongly suggest that EBOV
persisted in the survivor from 26 October 2014 (date of
Figure 1. Chains of transmission within the new Ebola virus disease cluster (A) and maximum likelihood phylogenetic analysis of the sequences from the new EVD cluster in
historical and geographical context (B). A, The chart depicts all patients involved in the cluster and the likely chains of transmission as revealed by epidemiological investigation
and virus sequencing. The timeline of events is shown on top. The blue circle depicts the 3 additional Liberian cases, which originated from case 6. B, The new sequences were
aligned with 1066 historical Ebola virus genome sequences and a maximum likelihood phylogenetic tree was estimated under the general time reversible + Gamma model using
RAxML [4]. Only the relevant part of the tree including the new sequences is shown. Abbreviations: +, positive Ebola virus reverse-transcription polymerase chain reaction; Ct,
cycle threshold; EBOV, Ebola virus; ETU, Ebola treatment unit; RT-PCR, reverse-transcription polymerase chain reaction.
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onset) to 9 April 2016 (last EBOV RNA–positive semen sample)
—that is, for 531 days. Remarkably, the virus in blood from 3
November 2014 differed from that in semen from 21 March
2016 by just 5 novel mutations (Supplementary Table 1) despite
being collected 504 days prior to the collection of the semen
sample. This equates to an evolutionary rate of 0.19 × 10−3 sub-
stitutions per site per year, roughly 6 times slower than the av-
erage evolutionary rate seen during human-to-human
transmission in this outbreak with reported mutation rates of
1.19 × 10−3 and 1.42 × 10−3, respectively (Supplementary Fig-
ure 2) [2, 3, 5]. The predicted effects on proteins encoded by
the EBOV genome are shown in Supplementary Table 1. Nota-
bly, one mutation is predicted to encode a premature stop
codon in the VP30 gene, truncating the expected gene product
by 7 amino acids.
We report on an EVD survivor in whom EBOV RNAwas de-
tected in seminal ﬂuid 531 days after onset of disease, the lon-
gest reported period of ﬁlovirus persistence in an individual.
Furthermore, we provide evidence that the persisting virus re-
mains viable and infectious during the long-term persistence.
Evidence for sexual transmission of the persisting EBOV in Feb-
ruary 2016, about 470 days after onset of symptoms in the sur-
vivor, is compelling. The absence of other cases in Guinea
around this time, the epidemiological link between the survivor
and case 1, and the identity of strains in the survivor’s seminal
ﬂuid and the acute cases strongly argue for the survivor being
the source of the new infections. EBOV persistence in seminal
ﬂuid is a known phenomenon, and previous reports have also
indicated that persisting virus may be sexually transmitted [6–
8]. However, so far the longest reported period of virus RNA
persistence in semen was 284 days [6], and reported likely trans-
mission events have been observed a maximum of 179 days after
onset of acute illness [7].
The reduced evolutionary rate of the virus during persistence
is plausible, given the presumed low level of replication in im-
mune-privileged sites such as the testes in the absence of detect-
able viremia. The few mutations that accumulated during the
500 days are of interest and deserve further functional investi-
gation. Nevertheless, the data presented here indicate that this
strain retained its pathogenic properties during persistence, as
evidenced by transmissibility, replication capacity (Ct values
around 20 in the acute cases of the cluster), and fatality ratio
of 80%. We cannot rule out the possibility that the survivor
was silently reinfected with Ebola after recovery. However this
seems unlikely as there have been no laboratory-conﬁrmed
cases of Ebola virus reinfection [9]. Additionally, no cases of
EVD had been detected in the N’Zérékoré region since January
2015 until the cluster of cases reported here. In the event of re-
infection, the lower-than-expected number of mutations seen
would make it unlikely that this case was the result of an unde-
tected continuation of a chain of human-to-human transmis-
sion among acute cases.
The case is also a great example demonstrating the yield of en-
hanced surveillance activities in the affected countries, cross-bor-
der cooperation, and improved capabilities to rapidly diagnose
and manage EVD patients. In addition, the report underlines
the value for outbreak response of combining ﬁeld epidemiology
with real-timemolecular epidemiology as well as the availability of
an up-to-date virus genome repository for the outbreak.
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